Small molecule conjugates for intracellular delivery of biologically active compounds
US-9301990-B2 · Apr 5, 2016 · US
Small molecule conjugates for intracellular delivery of biologically active compounds
US9968647B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9968647-B2 |
| Application number | US-201615090147-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 4, 2016 |
| Priority date | Dec 29, 2010 |
| Publication date | May 15, 2018 |
| Grant date | May 15, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides novel compounds and conjugates of these compounds useful for the delivery of biologically active substances. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to a delivery polymer to achieve in vivo mRNA knock down are disclosed therein.
First claim
Opening claim text (preview).
What is claimed is: 1. A conjugate prepared by a process comprising conjugating an oligonucleotide with a compound of formula (III): wherein the oligonucleotide is a single-stranded antisense oligonucleotide with at least one-naturally occurring nucleic acid nucleotide; and where the non-naturally occurring nucleotide is locked nucleic acid (LNA). 2. The conjugate of claim 1 wherein the oligonucleotide comprises a C-6 aminolinker. 3. A pharmaceutical composition comprising a conjugate according to claim 1 .
Assignees
Inventors
Classifications
2'-R Modification · CPC title
Acyclic or carbocyclic radicals, substituted by hetero rings · CPC title
Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids · CPC title
interfering nucleic acids [NA] · CPC title
Linear peptides containing at least one abnormal peptide link · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9968647B2 cover?
- The invention provides novel compounds and conjugates of these compounds useful for the delivery of biologically active substances. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to a delivery polymer to achieve in vivo mRNA knock down are disclosed therein.
- Who is the assignee on this patent?
- Hoffmann La Roche
- What technology area does this patent fall under?
- Primary CPC classification C12N15/87. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).